Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS.

Mol Cancer Res. 2019 Aug 29. doi: 10.1158/1541-7786.MCR-19-0419. [Epub ahead of print]

PMID:
31467113
2.

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.

Mol Cancer Ther. 2018 Aug;17(8):1648-1658. doi: 10.1158/1535-7163.MCT-17-1206. Epub 2018 May 10.

3.

Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.

Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, Itadani H, Kobayashi T, Hasako S, Kumazaki M, Mizuarai S, Oie S, Yano H.

Cancer Med. 2017 Jan;6(1):235-244. doi: 10.1002/cam4.959. Epub 2016 Nov 28.

4.

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.

Hirai H, Shimomura T, Kobayashi M, Eguchi T, Taniguchi E, Fukasawa K, Machida T, Oki H, Arai T, Ichikawa K, Hasako S, Haze K, Kodera T, Kawanishi N, Takahashi-Suziki I, Nakatsuru Y, Kotani H, Iwasawa Y.

Cell Cycle. 2010 Apr 15;9(8):1590-600. Epub 2010 Apr 15.

PMID:
20372067
5.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.

Hirai H, Takahashi-Suziki I, Shimomura T, Fukasawa K, Machida T, Takaki T, Kobayashi M, Eguchi T, Oki H, Arai T, Ichikawa K, Hasako S, Kodera T, Kawanishi N, Nakatsuru Y, Kotani H, Iwasawa Y.

Invest New Drugs. 2011 Aug;29(4):534-43. doi: 10.1007/s10637-009-9384-8. Epub 2010 Jan 19.

PMID:
20084424
6.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

Supplemental Content

Loading ...
Support Center